Diagnosing ATTR-CM (transthyretin amyloid cardiomyopathy) requires a specific sequence of tests, starting with clinical suspicion and imaging, then ruling out a related but different form of amyloidosis, and finally confirming the diagnosis with a nuclear bone scan or tissue biopsy. The process can be frustratingly slow: the median time from first suspicion to confirmed diagnosis is about 361 days, though that number has been improving as awareness grows.
ATTR-CM is a condition where a protein called transthyretin misfolds and deposits in the heart muscle, causing the walls to stiffen and thicken. It comes in two forms: a hereditary version caused by gene mutations and a “wild-type” version that typically affects men over 65. Both are diagnosed using the same core pathway, with genetic testing added at the end to distinguish between them.
Clinical Red Flags That Trigger Testing
Most diagnostic journeys begin when a cardiologist spots a pattern of findings that don’t quite fit the usual explanation. The classic trigger is thickened heart walls (12 mm or greater on echocardiogram) paired with an EKG that shows surprisingly low voltage. That mismatch is a hallmark of cardiac amyloidosis because the thickening comes from protein deposits, not from true muscle growth the way it does in hypertension or other causes of an enlarged heart. A combination of low EKG voltage and a thickened wall above about 2 cm can identify cardiac amyloidosis with 72% sensitivity and 91% specificity.
Several non-cardiac clues also raise suspicion, sometimes years before heart symptoms appear. Carpal tunnel syndrome is widely recognized as an early marker, particularly when it occurs in both hands. Lumbar spinal stenosis and spontaneous biceps tendon rupture are other orthopedic conditions linked to amyloid deposits in ligaments and tendons. A history of these problems in an older patient with unexplained heart wall thickening is a strong signal to pursue further testing.
Blood tests for two cardiac biomarkers can also help early in the process. If NT-proBNP (a marker of heart wall stress) is below 180 ng/L and high-sensitivity troponin T (a marker of heart muscle damage) is below 14 ng/L, ATTR-CM is very unlikely in someone with only mild suspicion.
Ruling Out Light Chain Amyloidosis
Before any imaging result can confirm ATTR-CM, doctors must first exclude a different type called AL amyloidosis. AL amyloidosis is caused by abnormal antibody fragments rather than transthyretin, and it requires completely different treatment, often chemotherapy. Misidentifying the type can be dangerous, so this step is considered the most critical part of the entire diagnostic process.
Three blood and urine tests are used together: serum protein electrophoresis with immunofixation (SPEP/IFE), a serum free light chain assay, and a 24-hour urine protein electrophoresis with immunofixation (UPEP/IFE). No single test is sensitive enough on its own. Combined, these three tests catch about 99% of AL amyloidosis cases. If all three come back negative, doctors can move forward with confidence that any positive bone scan result points to ATTR-CM rather than AL.
The Nuclear Bone Scan
The test that made non-invasive diagnosis of ATTR-CM possible is a nuclear medicine scan using a technetium-99m-labeled bone tracer, most commonly pyrophosphate (PYP) in the United States or DPD/HMDP in Europe. These tracers were originally designed for bone imaging, but they also bind strongly to transthyretin amyloid deposits in the heart.
During the scan, the tracer is injected into a vein, and images of the chest are taken, usually at one hour and again at three hours. Uptake in the heart is graded on a visual scale from 0 (no uptake) to 3 (uptake stronger than bone). A grade 2 or 3 result, combined with negative AL screening tests, is enough to confirm ATTR-CM without a biopsy. In a landmark study of over 1,200 patients, this combination had greater than 99% sensitivity and 86% specificity for ATTR-CM.
Timing matters. At one hour, the scan is very sensitive (about 98%) but produces more false positives because the tracer hasn’t fully cleared from the blood pool. By three hours, specificity improves to roughly 87%, though sensitivity drops to around 80%. Radiologists often use a heart-to-chest ratio measurement alongside the visual grade to improve accuracy, particularly when the result is borderline.
Cardiac MRI Findings
Cardiac MRI is not required for diagnosis when the bone scan is clearly positive, but it provides valuable additional information, especially in ambiguous cases. Two findings are particularly telling. First, a pattern of diffuse or subendocardial late gadolinium enhancement, which reflects protein deposits throughout the heart wall, can identify amyloidosis with 85 to 90% sensitivity and specificity. Second, the inability to “null” the heart muscle signal on a specific MRI sequence is considered diagnostic of amyloid infiltration.
Cardiac MRI can also measure the extracellular volume of the heart muscle, which reflects how much space is occupied by amyloid deposits rather than healthy cells. This measurement is considered a more reliable indicator of amyloid burden than other imaging markers and is useful for tracking disease progression over time.
When Biopsy Is Still Needed
If the bone scan is negative or only grade 1 but clinical suspicion remains high, or if the AL screening tests are abnormal, a tissue biopsy becomes necessary. The gold standard is an endomyocardial biopsy, where a small sample of heart tissue is stained with Congo red dye. Under polarized light, amyloid deposits produce a characteristic apple-green glow called birefringence.
A less invasive alternative is a fat pad aspiration, where a needle is used to collect a small sample of abdominal fat. This is simpler and lower risk, but it is less sensitive for cardiac amyloidosis specifically. Once amyloid is confirmed in any tissue sample, the protein type must be identified. This is done using antibody-based staining against known amyloid proteins, including transthyretin. In difficult cases, mass spectrometry can analyze the protein composition of the deposit directly.
Genetic Testing
Once ATTR-CM is confirmed, genetic testing of the TTR gene is recommended for every patient. This distinguishes hereditary ATTR from wild-type ATTR, which has major implications for family members who may carry the same mutation and for treatment decisions.
In the United States, the most common mutation by far is V142I (also called V122I), which accounts for about 84% of pathogenic variants identified through genetic testing programs. This mutation is carried by roughly 3 to 4% of Black Americans. The next most common are T60A (about 5% of cases) and V30M (about 4%), the latter being more commonly associated with nerve-predominant disease. If a mutation is found, first-degree relatives can be offered testing and monitored before symptoms develop.
Staging at Diagnosis
Once the diagnosis is confirmed, doctors stage the disease to estimate prognosis and guide treatment urgency. The most widely used system, developed at the Mayo Clinic from 360 patients, relies on two blood tests: troponin T and NT-proBNP. Stage I means both values are below their cutoffs (troponin T below 0.05 ng/mL and NT-proBNP below 3,000 pg/mL). Stage II means one value is elevated. Stage III means both are elevated, indicating more advanced disease.
A refined system from the UK National Amyloidosis Centre replaces troponin with kidney function (eGFR). Stage 1 requires NT-proBNP at or below 3,000 ng/L and eGFR at or above 45 mL/min. Stage 3, the most advanced, means NT-proBNP exceeds 3,000 and eGFR has dropped below 45. This staging helps set expectations: patients diagnosed at Stage I generally have significantly longer survival than those caught at Stage III, which underscores why earlier detection matters.
Why Diagnosis Still Takes Too Long
Despite the availability of a reliable non-invasive test, the median time from first suspicion to confirmed diagnosis was still nearly a year in a recent real-world analysis. Between 2018 and 2020, the median was 398 days. That improved to 277 days between 2021 and 2023 as awareness campaigns and clearer guidelines reached more cardiologists, but it remains a significant gap for a progressive disease. Even after diagnosis, patients waited a median of 84 days before starting treatment with a transthyretin stabilizer, though that delay also shortened over the same period, dropping from 111 days to 57 days.
The biggest factor in speeding diagnosis is recognizing the red flags early, particularly the combination of thickened heart walls with low EKG voltage, unexplained heart failure in an older adult, or a history of bilateral carpal tunnel surgery. If you or someone you know fits that profile, asking specifically about amyloidosis can help close the gap.